Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN)

Nephrology Dialysis Transplantation

Volumn 25, Issue 7, 2010, Pages 2168-2177

  Fogo, Agnes B ^a   Bostad, Leif ^b,c   Svarstad, Einar ^b,d   Cook, William J ^e   Moll, Solange ^f   Barbey, Federic ^g   Geldenhuys, Laurette ^h   West, Michael ⁱ   Ferluga, Dusan ^j   Vujkovac, Bojan ^k   Howie, Alexander J ^l   Burns, Áine ^m   Reeve, Roy ^h   Waldek, Stephen ⁿ   Noël, Laure Hélne ^h   Grünfeld, Jean Pierre ^o   Valbuena, Carmen ^h   Oliveira, João Paulo ^p   Müller, Justus ^h   Breunig, Frank ^q   Zhang, Xiao ^h   Warnock, David G ^r   more..

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e University of Alabama at Birmingham   (United States)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h Transplanatation Centre Centre Hospitalier Universitaire Vaudois University Hospital of Lausanne ^*  (United States)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j UNIVERSITY OF LJUBLJANA   (Slovenia)

^k General Hospital Celje   (Slovenia)

^l ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ HOPE HOSPITAL   (United Kingdom)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p HOSPITAL DE SÃO JOÃO   (Portugal)

^q UNIVERSITY OF WÜRZBURG   (Germany)

^r University of Alabama at Birmingham   (United States)

more..

Author keywords

chronic kidney disease; Fabry disease; pathology; sclerosis; scoring

Indexed keywords

CREATININE; GLYCOSPHINGOLIPID; PROTEIN;

ADULT; ARTICLE; CELL VACUOLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DELPHI STUDY; DISEASE COURSE; DISEASE SEVERITY; FABRY DISEASE; FABRY NEPHROPATHY; FEMALE; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYALINE DEGENERATION; INTIMA; KIDNEY BIOPSY; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MICROSCOPY; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; PROTEINURIA; SCORING SYSTEM; SEX DIFFERENCE; BIOPSY; CLINICAL TRIAL; FIBROSIS; FOCAL GLOMERULOSCLEROSIS; KIDNEY; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SEXUAL DEVELOPMENT;

ADULT; BIOPSY; DISEASE PROGRESSION; FABRY DISEASE; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; MALE; PODOCYTES; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS;

EID: 77954321307     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp528     Document Type: Article

References (37)

1. Desnick R, Ioannou Y, Eng C. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR Beaudet A, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001, 3733-3774
2. Branton MH, Schiffmann R, Sabnis SG et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-138
3. Schiffmann R, Warnock D, Banikazemi M et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascu-lar events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24: 2102-2111
4. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recom-binant human alpha-galactosidase A\replacement therapy in Fabry?s disease. N Engl J Med 2001; 345: 9-16
5. Thurberg BL, Rennke H, Colvin RB et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62: 1933-1946
6. Germain DP, Waldek S, Banikazemi M et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007; 18: 1547-1557
7. Fervenza F, Torra R, Warnock D. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics: Targets Ther 2008; 2: 1-22
8. Deegan PB, Baehner AF, Barba Romero MA et al. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43: 347-352
9. Wilcox WR, Oliveira JP, Hopkin RJ et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008; 93: 112-128
10. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-775 (Pubitemid 33032933)
11. Ortiz A, Oliveira JP, Waldek S et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008; 23: 1600-1607
12. Gubler MC, Lenoir G, Grunfeld JP et al. Early renal changes in hemizygous and heterozygous patients with Fabry?s disease. Kidney Int 1978; 13: 223-235
13. Sessa A, Toson A, Nebuloni M et al. Renal ultrastructural findings in Anderson-Fabry disease. J Nephrol 2002; 15: 109-112
14. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002; 13 (Suppl 2): S134-S138
15. Fischer EG, Moore MJ, Lager DJ. Fabry disease: a morphologic study of 11 cases. Mod Pathol 2006; 19: 1295-1301
16. Valbuena C, Carvalho E, Bustorff M et al. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. Virchows Arch 2008; 453: 329-338
17. Sessa A, Meroni M, Battini G et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis 2001; 24 (Suppl 2): 66-70
18. Svarstad E, Bostad L, Kaarboe O et al. Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry?s disease. Clin Nephrol 2005; 63: 394-401
19. Tondel C, Bostad L, Hirth A et al. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 2008; 51: 767-776
20. Tosoni A, Nebuloni M, Zerbi P et al. Ultrastructural study of renal involvement in two females with Anderson-Fabry disease. Ultrastruct Pathol 2005; 29: 203-207
21. Howie AJ, Ferreira MA, Adu D. Prognostic value of simple measurement of chronic damage in renal biopsy specimens. Nephrol Dial Transplant 2001; 16: 1163-1169
22. Stevens LA, Coresh J, Greene T et al. Assessing kidney function\measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483
23. Hutchings A, Raine R, Sanderson C et al. A comparison of formal consensus methods used for developing clinical guidelines. J Health Serv Res Policy 2006; 11: 218-224
24. KDOQI clinical practice guidelines and clinical practice recommen dations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12-S154
25. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psycholol Bull 1979; 86: 420-428
26. Ounpraseuth S, Rafferty TM, McDonald-Phillips RE et al. A method to quantify mouse coat-color proportions. PLoS ONE 2009; 4: e5414
27. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 1998; 24: 323-355
28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310
29. Grunfeld JP. How to improve the early diagnosis of Fabry disease? Kidney Int 2003; 64: 1136-1137
30. Aakre KM, Tondel C, Brun A et al. The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. Clin Nephrol 2009; 71: 118-124
31. Weening JJ, D?Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530
32. D?Agati V. Pathologic classification of focal segmental glomeru-losclerosis. Semin Nephrol 2003; 23: 117-134
33. Barbey F, Lidove O, Schwarting A. Fabry nephropathy: 5 years of enzyme replacement therapy\a short review. NDT Plus 2008; 1: 11-19
34. Feehally J, Barratt J, Coppo R et al. International IgA nephropathy network clinico-pathological classification of IgA nephropathy. Contrib Nephrol 2007; 157: 13-18
35. Fogo A, Breyer JA, Smith MC et al. AASK Pilot Study Investigators. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. Kidney Int 1997; 51: 244-252
36. Remuzzi G, Cravedi P, Perna A et al. Long-term outcome of renal transplantation from older donors. N Engl J Med 2006; 354: 343-352
37. Fogo A, Oliveira JP, Waldek S et al. Developing a chronicity index for kidney involvement in Fabry disease; report of the International Fabry kidney biopsy working group. J Am Soc Nephrol 2006; 17: 626 (abstract)